Background：
The 3rd Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area Award 2020, which sponsored by SINO-INNO Research, KPMG China, and organized by Guangdong Medical Valley is currently conducting business visits. The Top 50 Award 2020 is for national solicitation projects, and the authoritative judges will visit and investigate companies in the form of a combination of "online + offline", adopting the big data innovation standard selection system to help biotech companies with solid professional technology stand out and seize market opportunities, and strive to create the vane of the medical industry in the Bay Area.
On August 31, the authoritative judges of the Top 50 Award conducted an online visit to Israel JellyBand, includes Wang Yueyue, Partner of Tianchao Capital；Dr. Mingsheng Xie, Guangdong Medical Valley; Carman Deng, SVP, Healthcare Sector, HSBC Bank (China) Co Ltd；Wu Qianna, Research Director of SINO-INNO Research；Yan Lufeng, Researcher of SINO-INNO Research；Luo Jianying, Tax Lead Partner of the BioTech Group KPMG South China, and Shanghai Pudong Development Bank Co., Ltd., etc.. The authoritative judges conducted an in-depth understanding of the company's core products or services, technical team, patents and R&D status, and company financial status.
The founder and inventor of JellyBand, Prof. Shachar Richter; CO-CEO of CIJZ, Boaz Sacks; General Manger of CIJZ, Xixi Fu and the team attended the online meeting. CIJZ represents JellyBand in promoting financing expanding business in China.
Jellyfish are a global pandemic: They sting beach vacationers, Block power plants intakes disrupting supply of electricity, decrease fishery catches, decrease product values, and damage fishing gear. JellyBand’s is the first and only venture in the world addressing the Jellyfish problem in highly efficient and economical way. JellyBand is creating new cross industry food chain by recycling this growing global environmental problem into high demand line of medical and skin care products that are proven suitable for treatment of various acute medical problems
Professor Shachar Richter gave a detailed introduction to technology, products, market expectations and competition, and business models.
JellyBand has developed a cutting-edge wound dressing material applicable for fast and effective chronic wound healing. The wound dressing is composed of composite jellyfish nanofibers (that contain collagen and mucin) and nanoparticles of antibacterial silver, which exhibit all requisite qualities for fast and complete wound healing. Preclinical wound healing tests on pigs demonstrated full and fast recovery that were found to be superior to a leading commercial product. The use of JellyBand was found to reduce the healing period by 25% and to save more than 25% of the treatment expenses.
Notably, the material developed contains considerable amounts of collagen, highly needed material in cosmetics and artificial skin. Currently, the team is developing materials for these applications. The technology is protected by 4 patents (both granted and pending) and is licensed to JellyBand by Tel Aviv University.
At present, more than 160M patients suffer from chronic wounds. The numbers will continue to grow due to expected growth in life expectancy and diabetes related complications.Regenerative bandages and advanced wound care (Chronic wounds, Diabetic wounds, burns etc ) market size and growth data: Global Advanced Wound Care Market to Witness 6.3% CAGR During 2020 – 2025, Attaining the Market Size of USD 15.8 billion by 2025.